Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 601–700 of 982
Sourbier, C., Ricketts, C. J., Liao, P., Matsumoto, S., Wei, D., Lang, M., Railkar, R. S., Yang, Y., Wei, M.-H., Agarwal, P. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-55003-2 · Cited by 14
Brookes, P. S., Freeman, R. S., & Barone, M. C. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.03.019 · Cited by 14
Solaimuthu, B., Lichtenstein, M., Hayashi, A., Khatib, A., Plaschkes, I., Nevo, Y., Tanna, M., Pines, O., Shaul, Y. D., & Shaul, Y. D. (2022) · Cancers · doi:10.3390/cancers14225508 · Cited by 13
“Over the past twenty years, several mechanisms have been proposed to address the FH role in cancer, mainly focusing on accumulated fumarate due to enzyme loss [15,16].”
Kato, M., Maeda, K., Nakahara, R., Hirose, H., Kondo, A., Aki, S., Sugaya, M., Hibino, S., Nishida, M., Hasegawa, M., et al. (2023) · PNAS Nexus · doi:10.1093/pnasnexus/pgad306 · Cited by 13
Photoinducible Oncometabolite Detection
Kulkarni, R. A., Briney, C. A., Crooks, D. R., Bergholtz, S. E., Mushti, C., Lockett, S., Lane, A. N., Fan, T. W. ‐., Swenson, R. E., Linehan, W. M., et al. (2018) · ChemBioChem · doi:10.1002/cbic.201800651 · Cited by 13
Co-expression of HIF-1α, MDR1 and LAPTM4B in peripheral blood of solid tumors
Rehman, Z., Fahim, A., Bhatti, A., Sadia, H., & John, P. C. L. (2019) · PeerJ · doi:10.7717/peerj.6309 · Cited by 13
“This has been the case along with alteration in genes 294 encoding TCA intermediates in various solid tumors (LaGory & Giaccia 2016; Lee et al. 2016; 295 Pollard et al. 2005).”
MethodSaatchi, F., & Kirchmaier, A. L. (2019) · Genetics · doi:10.1534/genetics.119.302238 · Cited by 13
Genetics of Pheochromocytoma and Paraganglioma
Pereira, B. D., Luíz, H. V., Ferreira, A. G., & Portugal, J. (2019) · Codon Publications eBooks · doi:10.15586/paraganglioma.2019.ch1 · Cited by 13
“Finally, VHL (MIM *608537) inactivating mutations lead to an excess of HIF-2α due to the defective recognition of its hydroxylated isoform by the VHL protein and, ultimately, to cancer development and metastasis (34, 35).”
BackgroundFalegan, O. S., Egloff, S. A. A., Zijlstra, A., Hyndman, M. E., & Vogel, H. J. (2019) · Metabolites · doi:10.3390/metabo9080155 · Cited by 13
“The papillary RCC (PRCC) subtype is associated with mutations in the fumarase hydratase gene, where the function of the resultant and defective tricarboxylic acid (TCA) cycle enzyme fumarase is inhibited [5].”
BackgroundBao, X., Wu, J., Shuch, B. M., LoRusso, P. M., Bindra, R. S., & Li, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-47669-5 · Cited by 13
Germline DLST Variants Promote Epigenetic Modifications in Pheochromocytoma-Paraganglioma
Buffet, A., Zhang, J., Rebel, H. G., Corssmit, E. P. M., Jansen, J. C., Hensen, E. F., Bovée, J. V. M. G., Morini, A., Gimenez‐Roqueplo, A., Hes, F. J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa819 · Cited by 13
“Although the mechanisms by which mutations in metabolic enzymes promote tumor formation are not yet fully understood, inactivation of SDH, FH, and IDH1/2 leads to the accumulation of so-called “oncometabolites,” intermediary metabolites such as succinate, fumarate, and 2-hydroxyglutarate that are known to inhibit diox…”
BackgroundMitochondrial Tumor Suppressors—The Energetic Enemies of Tumor Progression
Jakoubě, P., Cutano, V., González-Morena, J. M., & Keckesova, Z. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0518 · Cited by 13
Kamai, T., Tomosugi, N., Abe, H., Kaji, Y., Oyama, T., & Yoshida, K. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131114518 · Cited by 13
Siebers, E. M., Choi, M. J., Tinklenberg, J. A., Beatka, M. J., Ayres, S., Meng, H., Helbling, D. C., Takizawa, A., Bennett, B., Garces, A. M., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nly042 · Cited by 13
Abnormal cellular translocation of α‐internexin in spinal motor neurons of Dystonia musculorum mice
Tseng, K., Chau, Y., Yang, M., Lu, K., & Chien, C. L. (2007) · The Journal of Comparative Neurology · doi:10.1002/cne.21606 · Cited by 13
Malthièry, Y., & Savagner, F. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72588-4 · Cited by 13
“Par contre, les auteurs retrouvent bien une accumulation de succinate dont le rôle majeur dans ces tumeurs a été démontré presque simultanément par deux autres équipes [3, 11].”
The Role of 2-Oxoglutarate-Dependent Oxygenases in Hypoxia Sensing
Wilkins, S. E., Flashman, E., Scotti, J. S., Hopkinson, R. J., Chowdhury, R., & Schofield, C. J. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782621959-00169 · Cited by 12
An Oncometabolite Isomer Rapidly Induces a Pathophysiological Protein Modification
Bergholtz, S. E., Briney, C. A., Najera, S. S., Perez, M., Linehan, W. M., & Meier, J. L. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00044 · Cited by 12
Gregorio, E. D., Miolo, G., Saorin, A., Steffan, A., & Corona, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115574 · Cited by 13
“The LoF of SDH occurs by the loss of heterozygosity (LOH) due to the second allele deletion that arrests the succinate- fumarate conversion [37].”
BackgroundCelada, L., Cubiella, T., San‐Juan‐Guardado, J., Martínez, A. S. J., Valdés, N., Jiménez‐Fonseca, P., Díaz, I., Enguita, J. M., Astudillo, A., Álvarez-González, E., et al. (2022) · Cancers · doi:10.3390/cancers14122986 · Cited by 12
Genitourinary Cancer Predisposition Syndromes
Gallagher, D. J., Feifer, A. H., & Coleman, J. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.06.002 · Cited by 12
Altered Dynamics of Intestinal Cell Maturation in Apc1638N/+ Mice
Wang, D., Pezo, R. C., Corner, G. A., Sison, C. P., LESSER, M. L., Shenoy, S. M., Mariadason, J. M., Singer, R. H., & Augenlicht, L. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4593 · Cited by 12
Therapeutic Strategies for Hereditary Kidney Cancer
Sidana, A., & Srinivasan, R. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0537-6 · Cited by 12
Pheochromocytoma/Paraganglioma: A Poster Child for Cancer Metabolism
Tevosian, S. G., & Ghayee, H. K. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-01991 · Cited by 12
New cancer targets emerging from studies of the Von Hippel‐Lindau tumor suppressor protein
Kaelin, W. G. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05781.x · Cited by 12
Uchiumi, F., Larsen, S. H., & Tanuma, S. (2015) · InTech eBooks · doi:10.5772/59588 · Cited by 12
Kundu, A., Brinkley, G. J., Nam, H., Karki, S., Kirkman, R. L., Pandit, M., Shim, E., Widden, H., Liu, J., Heidarian, Y., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci171294 · Cited by 11
Hart, M. L., Sokolov, D., Danquah, S., Zheng, E., Doan, A. D., Davidsen, K., MacPherson, D. P., & Sullivan, L. B. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01524-w · Cited by 11
Huang, B.-L., Liu, Q., Teng, Y.-Y., Peng, S., Liu, Z., Li, M., Liang, J., Zhang, Y., & Wang, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1167796 · Cited by 11
Marden, J. H., Langford, E. A., Robertson, M. A., & Fescemyer, H. W. (2020) · Evolution · doi:10.1111/evo.14095 · Cited by 11
“Impeding SDH causes succinate to accumulate in cells, which activates the hypoxia inducible factor (HIF) pathway (Pollard et al. 2005).”
BackgroundIdentification of metabolic changes leading to cancer susceptibility in Fanconi anemia cells
Abad, E., Samino, S., Grodzicki, R. L., Pagano, G., Trifuoggi, M., Graifer, D., Potěšil, D., Zdráhal, Z., Yanes, Ó., & Lyakhovich, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.12.010 · Cited by 11
Sesti, F. F., Feola, T., Puliani, G., Centello, R., Vito, V. D., Bagni, O., Lenzi, A., Isidori, A. M., Cantisani, V., Faggiano, A., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.677983 · Cited by 11
“org 7 Indeed, the tumorigenesis of PGLs seems partly related to a pseudo-hypoxic drive (59).”
BackgroundFan, Z., Li, L., Li, X., Zhang, M., Dou, M., Zhao, J., Cao, J., Deng, X., Zhang, M., Li, H., et al. (2019) · Aging · doi:10.18632/aging.101761 · Cited by 11
Idle, J. R., Seipel, K., Bacher, U., Pabst, T., & Beyoğlu, D. (2020) · Cancers · doi:10.3390/cancers12102842 · Cited by 11
MITOCHONDRIA: Succinate dehydrogenase subunit B-associated phaeochromocytoma and paraganglioma
Dona, M., Neijman, K., & Timmers, H. J. L. M. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.105949 · Cited by 11
Reprogrammed mitochondria: a central hub of cancer cell metabolism
Ciccarone, F., & Ciriolo, M. R. (2024) · Biochemical Society Transactions · doi:10.1042/bst20231090 · Cited by 10
The emerging role of metabolic interventions in uveal melanoma
Kuranaga, Y., Hatem, Y., Grossniklaus, H. E., Ali, S. S., & Meir, E. G. V. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.10.002 · Cited by 10
Høgh, R. I., Droujinine, A., Møller, S. H., Jepsen, S. D., Mellergaard, M., Andresen, L. O., & Skov, S. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.1900740 · Cited by 10
Oncometabolites as Regulators of DNA Damage Response and Repair
Gueble, S. E., & Bindra, R. S. (2021) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2021.09.004 · Cited by 10
Wang, L., Du, R., Han, L., Yang, R., & Li, Y. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101963 · Cited by 10
“Subsequently, HIF-α activation initiates the HIF pathway, intricately linked to tumorigenesis and metastasis [7,8].”
Hernández‐Ochoa, B., Fernández-Rosario, F., Castillo‐Rodríguez, R. A., Marhx-Bracho, A., Cárdenas‐Rodríguez, N., Martínez‐Rosas, V., Morales-Luna, L., González‐Valdez, A., Calderón-Jaimes, E., de la Cruz, V. P., et al. (2021) · Genes · doi:10.3390/genes12091335 · Cited by 10
Jochmanová, I., & Lazúrová, I. (2014) · Biomedical Papers · doi:10.5507/bp.2014.021 · Cited by 10
Comparison of metabolite profiles in U87 glioma cells and mesenchymal stem cells
Jürchott, K., Guo, K., Catchpole, G., Feher, K., Willmitzer, L., Schichor, C., & Selbig, J. (2011) · Biosystems · doi:10.1016/j.biosystems.2011.05.005 · Cited by 10
Potentiation of Anti-Cancer Treatment by Modulators of Energy Metabolism
Shoshan, M. C. (2013) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201011314030007 · Cited by 10
Marletta, S., Marcolini, L., Caliò, A., Pedron, S., Antonini, P., Martelli, F. M., Stefanizzi, L., & Martignoni, G. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04041-5 · Cited by 9
Mühling, J., Tiefenbach, M., López‐Barneo, J., Piruat, J. I., García‐Flores, P., Pfeil, U., Gries, B., Mühlfeld, C., Weigand, M. A., Kummer, W., et al. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.09.023 · Cited by 9
Wortham, N. C., Alam, N. A., Barclay, E., Pollard, P. J., Wagner, B. E., Manek, S., Elia, G., & Tomlinson, I. P. M. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.02.106 · Cited by 9
Self-citationCancer Metabolism and Its Therapeutic Implications
Logsdon, W. L. C. D., & Abbruzzese, J. L. (2013) · Journal of Cell Science & Therapy · doi:10.4172/2157-7013.1000143 · Cited by 9
“By oxidizing the Prolyl Hydroxylase (PHD) cofactors ferrous iron and ascorbate, ROS inhibits PHD activity under normoxic condition and stabilizes HIF1α and therefore alters metabolism into aerobic glycolysis which favors NADPH production through the PPP and allows cancer cells to adapt to ROS stress [101].”
BackgroundInfluentialTao, Y., Feng, L., Li, R., Shen, J., & Wang, Z.-X. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.05.022 · Cited by 9
Singh, C., Bindra, R. S., Glazer, P. M., Vasquez, J. C., & Pashankar, F. (2022) · Pediatric Blood & Cancer · doi:10.1002/pbc.30020 · Cited by 9
Maher, E. R. (2006) · British Medical Bulletin · doi:10.1093/bmb/ldl002 · Cited by 9
Recent developments in eosinophilic renal neoplasms: what's new, true and important?
Trpkov, K., Siadat, F., & Saleeb, R. (2025) · Histopathology · doi:10.1111/his.70001 · Cited by 8
Gul, A. E., Keser, S. H., Barışık, N. Ö., Gürbüz, Y. S., Şensu, S., & Erdoğan, N. (2021) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2021.22.6.1721 · Cited by 8
“Fumaratehydratase (FH) and SDH (SDHB, -C and -D) are mitochondrial Krebs cycle enzymes which act as tumor suppressors (Nazar et al., 2019; Pollard et al., 2005).”
BackgroundSDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?
Branzoli, F., Salgues, B., Marjańska, M., Laloi-Michelin, M., Herman, P., Collen, L. L., Delemer, B., Mallart-Riancho, J., Kuhn, E., Jublanc, C., et al. (2022) · Endocrine Related Cancer · doi:10.1530/erc-22-0198 · Cited by 9
Bioinformatics analysis and expression study of fumarate hydratase in lung cancer
Ming, Z., Jiang, M., Li, W., Fan, N., Deng, W., Zhong, Y., Zhang, Y., Zhang, Q., & Yang, S. (2014) · Thoracic Cancer · doi:10.1111/1759-7714.12127 · Cited by 8
Fine mapping of the uterine leiomyoma locus on 1q43 close to a lncRNA in the RGS7-FH interval
Aïssani, B., Zhang, K., Mensenkamp, A. R., Menko, F. H., & Wiener, H. W. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0208 · Cited by 8
Racial disparity in metabolic regulation of cancer
Singh, P. K. (2017) · Frontiers in bioscience · doi:10.2741/4543 · Cited by 9
“Genetic mutations in SDH and FH results in activation of HIF-1a-mediated glucose utilization (63).”
Bernardo‐Castiñeira, C., Sáenz‐de‐Santa‐María, I., Valdés, N., Astudillo, A., Balbín, M., Pitiot, A. S., Jiménez‐Fonseca, P., Scola, B., Tena, I., Molina‐Garrido, M., et al. (2018) · Head & Neck · doi:10.1002/hed.25386 · Cited by 8
“VHL 1 (1) 2 (3) RET 0 (0) 1 (2) SDHx wild type 48 (49) 22 (37)”
Bacci, M., Ippolito, L., Magnelli, L., Giannoni, E., & Chiarugi, P. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.009 · Cited by 8
Ma, X., Cui, Y., Gao, Y., Zhang, X., Nie, M., & Tong, A. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14866 · Cited by 8
Chiu, D. K., Zhang, M. S., Tse, A. P., & Wong, C. C. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9027-6_6 · Cited by 8
Microenvironmental Metabolites in the Intestine: Messengers between Health and Disease
Zaurito, A. E., & Tschurtschenthaler, M. (2022) · Metabolites · doi:10.3390/metabo12010046 · Cited by 8
Biomarker Discovery for Drug Development and Translational Medicine Using Metabonomics
Keun, H. C. (2008) · Ernst Schering Research Foundation workshop/Ernst Schering Foundation Symposium proceedings · doi:10.1007/2789_2008_090 · Cited by 8
Crooks, D. R., Cawthon, G. M., Fitzsimmons, C. M., Perez, M., Ricketts, C. J., Vocke, C. D., Yang, Y., Middelton, L. A., Nielsen, D., Schmidt, L. S., et al. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad131 · Cited by 8
Wang, Y., Vadhan, A., Wu, C.-H., Hsu, C., Chen, Y., Chen, Y.-K., Chen, P., Nguyen, H., Chang, Y.-C., & Yuan, S. F. (2023) · Oncology Reports · doi:10.3892/or.2023.8620 · Cited by 7
Research Translation and Personalized Medicine
Brugarolas, J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-2400-0_8 · Cited by 7
Back to the Future: Molecular Biology Meets Metabolism
McKnight, S. L. (2011) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2012.76.013722 · Cited by 7
“…restriction of yeast, worms, and flies, to mammalian circadian rhythm, it was collectively argued that the activity of sirtuins is controlled by the cellular abundance of NADþ (Bellet et al. 2012; Canto and Auwerx 2012; Guarente 2012; Ramsey and Bass 2012; Saini et al. 2012; Sun et al. 2012).”
BackgroundHead and Neck Malignant Paragangliomas: Experience from a Single Institution
Ding, Y., Li, L., Han, D.-M., Wang, S., & Chen, X. (2021) · Ear Nose & Throat Journal · doi:10.1177/01455613211052338 · Cited by 7
“30 This study identi fi ed a patient with malignant paraganglioma who carried the SDHD germline mutation.”
BackgroundOxidative Stress and Redox-Signaling in Renal Cell Cancer
Block, K. L. (2012) · InTech eBooks · doi:10.5772/26747 · Cited by 7
“Stabilization of HIF-alpha binds to the HIF-beta subunit (ARNT) and the dimer translocates to the nucleus and binds to HIF-responsive elements, HREs (core sequence of 5′-RCGTG-3′ in the enhancer elements of target genes) which drives the transcriptional activation of over a hundred genes that support renal carcinogene…”
BackgroundInfluentialMilione, M., Pusceddu, S., Gasparini, P., Melotti, F., Maisonneuve, P., Mazzaferro, V., de Braud, F., & Pelosi, G. (2012) · Cancers · doi:10.3390/cancers4030808 · Cited by 7
Metabolomic Studies on Cancer and on Anticancer Drugs by NMR Ex Vivo
Chung, Y., & Griffiths, J. R. (2011) · Wiley eBooks · doi:10.1002/9780470034590.emrstm1093 · Cited by 7
Self-citationThe clinical landscape of HIF2α inhibitors in oncology
Saad, E., Machaalani, M., McDermott, D. F., & Choueiri, T. K. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01145-y · Cited by 7
“Additionally, the phase Ib–II STELLAR-009 (NCT06191796) trial was initiated to evaluate casdatifan in combination with zanzalintinib, a novel, multi-targeted TKI with activity against VEGFR, MET and the TAM kinases (TYRO3, AXL, MER), as well as the triplet combination of cas-datifan, zanzalintinib and nivolumab in pat…”
InfluentialTeriflunomide – The common drug with underestimated oxygen - Dependent anticancer potential
Otto‐Ślusarczyk, D., Graboń, W., Mielczarek‐Puta, M., & Chrzanowska, A. (2021) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2021.101141 · Cited by 6
“It should result in malonate activity potentialization at 10% O2 [23].”
BackgroundFunctional Characterization of FH Mutation c.557G>A Underlies Uterine Leiomyomas
Li, P., Wu, Y., Wu, H., Xiong, Q., Zhao, N., Chen, G., Wu, C., & Han, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031452 · Cited by 6
Genetic insights into the hypoxia-inducible factor (HIF) pathway
Kiriakidis, S., Esteban, M. A., & Maxwell, P. H. (2007) · Advances in Enzyme Regulation · doi:10.1016/j.advenzreg.2006.12.009 · Cited by 6
Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets
Messer, J. C., Drabick, J. J., & Kaag, M. G. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-6176-0_13 · Cited by 6
Tracy, J. C., & Wein, R. O. (2012) · Head & Neck · doi:10.1002/hed.23098 · Cited by 6
“Hypoxia inducible factor a1 is involved in a cellular hypoxia response that leads to angiogenesis, cell growth, and mitosis.(6,7) However, this theory is likely not the whole story as loss of function of SDH secondary to mutations in other subunits (for example, SDH subunit A) do not cause neoplastic disease.”
BackgroundTranscription | Regulation of Gene Transcription by Hypoxia-Inducible Factor 1α
Child, F., Frost, J., Shakir, D., Wilson, J. W., & Rocha, S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00033-5 · Cited by 6
Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H., Liu, L., Liu, Y., Yang, C., Xu, Y., et al. (2015) · Europe PMC (PubMed Central) · Cited by 6
Niu, L., Kang, X., Zheng, J., Wu, F., Liu, S., Liu, H., Liu, H., Wang, J., Fan, D., Nie, Y., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107996 · Cited by 5
What do stimulated beta cells have in common with cancer cells?
Marhl, M. (2024) · Biosystems · doi:10.1016/j.biosystems.2024.105257 · Cited by 5
Yamaguchi, Y., Yokoyama, M., Takemoto, A., Nakamura, Y., Fukuda, S., Uehara, S., Tanaka, H., Yoshida, S., Matsuoka, Y., & Fujii, Y. (2022) · IJU Case Reports · doi:10.1002/iju5.12520 · Cited by 5
Shi, Y. X., Xu, Y., Wang, C., Chen, Y., Ren, X., Kang, Y., & Wang, C. (2023) · Genes · doi:10.3390/genes14030744 · Cited by 5
Park, M. N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512037 · Cited by 5
Pseudohypoxia, Mitochondrial Mutations, the Warburg Effect, and Cancer.
Sanders, E. (2012) · Cited by 5
Divatia, M. K., & El‐Zaatari, Z. M. (2020) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_877_19 · Cited by 5
Regulation of 5-Hydroxymethylcytosine Distribution by the TET Enzymes
Cao, J. Z., Hains, A. E., & Godley, L. A. (2019) · RNA technologies · doi:10.1007/978-3-030-14792-1_10 · Cited by 5
Myopathy in hereditary leiomyomatosis and renal cell cancer in an extended family
España, A., Ornilla, E., Zárate, R., Bazo, I. G., & Briones, P. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13504 · Cited by 5
Zhang, Z. (2014) · KU ScholarWorks (The University of Kansas) · Cited by 5
Alam, M. M., Lal, S., FitzGerald, K. E., & Li, Z. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0186-5 · Cited by 5
Zhou, S. X., Madden, B. J., Charlesworth, C. M., Hitosugi, T., Favier, J., & Maher, L. J., III (2026) · Journal of Biological Chemistry · doi:10.1101/2025.08.01.668168 · Cited by 4
Cubiella, T., Alba‐Linares, J. J., San‐Juan‐Guardado, J., Suárez‐Priede, Á., Gomez-Suarez, N., Tous, M. D. C., Bancos, I., Villabona, C. M., Piñol, T. S., Tena, I., et al. (2026) · Communications Biology · doi:10.1038/s42003-026-09543-9 · Cited by 4
“However, germline mutations in SDHB , SDHD , SDHA , or SDHC (collectively SDHx ) disrupt this process, leading to oncometabolite accumulation that drives epigenetic reprogramming 6,7 and activation of hypoxia-inducible factor (HIF) target genes 8 – 10 .”
Metabolic permissiveness: how tissue context shapes cancer
Moschandrea, C., & Frezza, C. (2026) · Genes & Development · doi:10.1101/gad.353516.125 · Cited by 4
“…another onco-metabolite that competitively inhibits α KGDs, such as prolyl hydroxylases (PHDs), thereby stabilizing HIF-1 α and promoting a pseudohypoxic transcriptional program (Baysal et al. 2000; Gottlieb and Tomlinson 2005; Pollard et al. 2005, 2006; Selak et al. 2005; Bardella et al. 2011b).”
Karsikas, S. (2015) · Cited by 4
Allal, B.-E., Bounaama, A., Silva, D., Quintas, C., Dahlouk, S. I., Gonçalves, J., & Djerdjouri, B. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02403-x · Cited by 4
Miltenburg, J. B., Gorissen, M., van Outersterp, I., Versteeg, I., Nowak, A., Rodenburg, R. J., van Herwaarden, A. E., Olthaar, A. J., Küsters, B., Conrad, C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137262 · Cited by 4
“Defects in SDH therefore lead to an accumulation of succinate and defective energy metabolism [7,8].”
BackgroundSex Cord Stromal Tumors of the Testis
Colecchia, M., Fiorentino, M., Ricci, C., Tenace, N. P., Barella, M., & Pini, G. M. (2024) · Surgical pathology clinics · doi:10.1016/j.path.2024.08.009 · Cited by 4
Modeling dioxygenase enzyme kinetics in familial paraganglioma
Peters, J. P., Her, Y. F., & Maher, L. J. (2015) · Biology Open · doi:10.1242/bio.013623 · Cited by 4
“To date, a number of diseases have been hypothesized to involve PHD inhibition and HIFα activation (Pollard et al., 2005; Selak et al., 2005; Zhao et al., 2009).”
BackgroundGlycolytic Pathway as a Target for Tumor Inhibition
Lu, W., & Huang, P. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_5 · Cited by 4
Hereditary Renal Cell Carcinoma
Baba, M., Schmidt, L. S., & Linehan, W. M. (2017) · Springer eBooks · doi:10.1007/978-4-431-55531-5_2 · Cited by 4
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.